Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, transformed indolent B-cell lymphoma, or high-grade B-cell lymphoma
• People who received a standard-of-care, FDA-approved CAR T-cell therapy (targeting CD19) outside of a clinical trial
• People aged 18 or older
• People with a general health/activity level rated 0, 1, or 2 on a standard medical scale (meaning able to carry out at least some daily activities — confirm with trial site)
• People whose cancer showed a partial response (meaning it reduced but did not fully disappear) about 30 days after CAR T-cell therapy, based on standard response criteria
• People for whom at least 30 days have passed since their CAR T-cell therapy infusion
• People whose cancer cells show no detectable CD19 protein after CAR T-cell therapy
• People who have not received any additional cancer treatment after CAR T-cell therapy, except for palliative radiation therapy
• People whose blood cell counts (white cells and platelets) are at acceptable levels without needing growth factor support or blood transfusions for at least 3 days before the screening assessment
• People whose kidneys are functioning at an acceptable level (confirm with trial site)
• People whose liver function tests are within acceptable ranges (confirm with trial site)
• People whose heart is pumping adequately (at least 45% efficiency) with no significant fluid around the heart
• People whose blood oxygen level is above 92% while breathing normal room air
• People with no evidence or suspicion of lymphoma affecting the brain or spinal cord
• Women who could potentially become pregnant must have a negative pregnancy test before joining
• People who have fully recovered from any serious side effects (specifically CRS or ICANS) related to their CAR T-cell therapy

Who may not be able to join:

• People with significant fluid build-up in the abdomen requiring drainage, or fluid around the lungs causing breathing difficulty
• People with a history of another cancer (other than certain non-invasive or easily treated skin or localised cancers) unless they have been cancer-free for at least 12 months
• People with a history of a specific transformation of chronic lymphocytic leukaemia (CLL) called Richter's transformation
• People whose most recent treatment before this trial was CAR T-cell therapy received as part of another clinical trial
• People who have previously been treated with loncastuximab tesirine (lonca)
• People with an active infection that is not under control or that requires intravenous antibiotics (minor infections that are responding to treatment may be considered — confirm with trial site)
• People with a known history of HIV, hepatitis B, or hepatitis C where the virus is still detectable in the blood
• People with lymphoma actively involving the heart chambers
• People who have had a heart attack, heart procedure, unstable chest pain, or other significant heart condition within the past 12 months
• People with a primary immune system deficiency condition
• People with a history of an autoimmune disease (such as Crohn's disease, rheumatoid arthritis, or lupus) that has caused organ damage or required ongoing immune-suppressing treatment within the last 2 years
• People with a history of a serious blood clot in the veins or lungs within 1 month of joining (at the investigator's discretion)
• People with any medical condition that could interfere with safely assessing the treatment's effects
• People with a history of a severe allergic reaction to any medication used in this trial
• Women who are pregnant or breastfeeding, due to potential risks to the baby
• People who are not willing to use effective contraception during and after the trial — women of childbearing potential must use highly effective contraception for 9 months after the last dose of lonca, and men with female partners who could become pregnant must use a condom for 6 months after the last dose
• People who, in the investigator's judgement, are unlikely to complete all required trial visits and procedures

Important: Always verify eligibility with the trial site directly before applying.